Clonal Hematopoiesis in Newly Diagnosed Multiple Myeloma: Associations With Neutropenia, Supportive Care Burden, and Survival [0.03%]
克隆性血液细胞增多在新诊断的多发性骨髓瘤中的相关性：与中性粒细胞减少、支持治疗负担及生存期的相关性研究
Ahmet Yigitbasi,Fulya Oz Puyan,Hakki Onur Kirkizlar et al.
Ahmet Yigitbasi et al.
Background: Clonal hematopoiesis (CH) is increasingly recognized as a clinically relevant host factor in newly diagnosed multiple myeloma (NDMM), with potential implications for frailty, treatment tolerance, supportive ca...
SOHO State of the Art Updates and Next Questions | Best of Stem Cell Transplant: Recent Advances in Allogeneic Hematopoietic Cell Transplantation [0.03%]
SOHO 最新技术更新及未来展望| 干细胞移植精华：异基因造血干细胞移植近期进展
Molly Gilligan,Alexandra Gomez-Arteaga
Molly Gilligan
Allogeneic hematopoietic cell transplantation is undergoing rapid transformation, propelled by a wave of practice-changing studies that are reshaping how donors are selected, how graft-versus-host disease (GVHD) is prevented, and how post-t...
Pre-CAR-HEMATOTOX at Leukapheresis Predicts Delayed Platelet Recovery After Idecabtagene Vicleucel in Multiple Myeloma [0.03%]
CAR-T回输前外周血中的造血细胞毒性与Idecabtagene vicleucel治疗多发性骨髓瘤后血小板恢复延迟有关
Taku Kikuchi,Moe Nomura-Yogo,Ukyo Kondo et al.
Taku Kikuchi et al.
Background: The CAR-HEMATOTOX score has been associated with hematologic toxicity after chimeric antigen receptor T-cell therapy, but it is usually assessed shortly before lymphodepletion, when hematopoietic reserve may a...
Dose Optimization of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis of 50 mg Versus 100 mg Once Daily [0.03%]
达沙替尼治疗慢性期慢性髓性白血病的剂量优化：每日一次50毫克与100毫克的系统评价和meta分析
Mohammed Abdulgayoom,Motaz Almahmood,Rasha Kaddoura et al.
Mohammed Abdulgayoom et al.
Dasatinib 100 mg once daily is effective for chronic-phase chronic myeloid leukemia (CP-CML), but dose-related toxicity may limit long-term tolerability. We therefore evaluated whether dasatinib 50 mg once daily as an initial dose strategy ...
Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management [0.03%]
belantamab mafodotin治疗多发性骨髓瘤的临床开发及剂量优化和毒性管理策略实务
Roberto Mina,Evangelos Terpos,Lorenzo Cani et al.
Roberto Mina et al.
Belantamab mafodotin (belamaf) is an antibody-drug conjugate targeting B-cell maturation antigen on plasma cells. The phase III DREAMM-7 and DREAMM-8 trials, in which belamaf was combined with bortezomib-dexamethasone or pomalidomide-dexame...
Second Primary Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Comprehensive Review [0.03%]
慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的继发性恶性肿瘤：全面综述
Julian J Guetta-Weiss,Danielle M Brander
Julian J Guetta-Weiss
Patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) have benefited significantly over the last decade from the approval of several novel, targeted therapeutic agents, resulting in prolonged overall survival. Ho...
SOHO State-of-the-Art Updates and Next Questions: Current Approach to Waldenström Macroglobulinemia [0.03%]
工作型家庭办公室最新进展和下一个问题：Waldenström巨球蛋白血症的当前处理方法
Prashant Kapoor,Udit Yadav,Camille Edwards et al.
Prashant Kapoor et al.
Waldenström macroglobulinemia (WM) or Immunoglobulin M (IgM) lymphoplasmacytic lymphoma is a heterogeneous clinicopathologic entity with distinguishing features that include circulating monoclonal IgM, lymphoplasmacytic marrow infiltrate, ...
Letermovir for Cytomegalovirus Prophylaxis in Patients With T-PLL Treated With Alemtuzumab [0.03%]
阿伦单抗治疗T细胞淋巴细胞白血病的患者中利托莫韦用于预防巨细胞病毒感染
John C Reneau,Ying Huang,Zachary Braunstein et al.
John C Reneau et al.
Knowledge, Awareness, and Practice Patterns of Nephrologists in the Diagnosis and Management of Multiple Myeloma (MIND-MM Study): A Cross-Sectional, Web-Based, CHERRIES-Compliant Survey with Position Statement from the Indian Myeloma Academic Groupe (IMAGe) and Indian Society of Nephrology (ISN) [0.03%]
印度MYDRMM研究：肾脏病专家在诊断和治疗多发性骨髓瘤的知识、认知和实践模式（MIND-MM研究）：符合CHERRIES的横断面网络调查及印度骨髓瘤学术团体（IMAGe）和印度肾病学会（ISN）立场声明
Uday Yanamandra,Raja Ramachandran,Vinay Sakhuja et al.
Uday Yanamandra et al.
Background: Multiple myeloma (MM) frequently presents with renal manifestations, positioning nephrologists as key frontline clinicians for early diagnosis. However, the knowledge, awareness, and practice (KAP) patterns of...
Association of GLP1-Receptor Agonists With Risk of Hematologic Malignancies in People With Diabetes [0.03%]
糖尿病患者使用胰高血糖素样肽-1受体激动剂与血液系统恶性肿瘤风险之间的关系
Samuel Ramos,Shin Zaw,Allison Carilli et al.
Samuel Ramos et al.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are widely used for the management of diabetes mellitus and obesity. Despite growing literature on GLP-1RA use and obesity-related cancers, the association b...